Multiplex Biomarker Imaging Market Report 2026

Multiplex Biomarker Imaging Market Overview

• Multiplex Biomarker Imaging market size has reached to $0.54 billion in 2025 • Expected to grow to $0.86 billion in 2030 at a compound annual growth rate (CAGR) of 9.5% • Growth Driver: Rising Chronic Disease Prevalence Surge Multiplex Biomarker Imaging Market • Market Trend: Innovative Breakthrough For Revolutionizing Multiplex Biomarker Imaging • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Multiplex Biomarker Imaging Market?

Multiplex biomarker imaging is a technique that allows for the simultaneous detection and analysis of multiple biomarkers within a single sample, enabling the visualization of complex biological processes and molecular profiles. This method uses advanced imaging technologies to map the spatial distribution of biomarkers within tissues, providing detailed insights into cellular interactions and microenvironments. The main component types of multiplex biomarker imaging are instruments, software, and services. An instrument is a tool or device used to do a particular task, especially a scientific task, or a device used for making measurements of something such as speed, height, or sound. The imaging techniques include immuno fluorescence (IF) assay, tissue microarray (TMA) assay, immunohistochemistry (IHC) assay, fluorescent in the situ hybridization (FISH) assay, and toponome imaging system (TIS) for applications such as drug safety, oncology studies, and genetic characterization studies. The end users include research institutes government and private, clinical labs, pharmaceutical, and biotechnology.

What Is The Multiplex Biomarker Imaging Market Growth Forecast?

The multiplex biomarker imaging market size is expected to see strong growth in the next few years. It will grow to $0.86 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to advancements in imaging platforms, rising demand for personalized medicine, expansion of multiplex assay applications, growth in pharmaceutical biomarker programs, increased investment in spatial biology research. Major trends in the forecast period include increasing use of multiplex imaging in oncology research, growing demand for high-resolution tissue mapping, rising adoption of advanced immunofluorescence techniques, expansion of automated image analysis solutions, integration of multiplex imaging with drug discovery platforms.

Global Multiplex Biomarker Imaging Market Segmentation

1) By Component Type: Instruments, Software, Services 2) By Imaging Techniques: Immunofluorescence (IF) Assay, Tissue Microarray (TMA) Assay, Immunohistochemistry (IHC) Assay, Fluorescent In Situ Hybridization (FISH) Assay, Toponome Imaging System (TIS) 3) By Application: Drug Safety, Oncology Studies, Genetic Characterization Studies 4) By End User: Research Institutes, Government And Private, Clinical Labs, Pharmaceutical And Biotechnology Subsegments: 1) By Instruments: Imaging Systems (Microscopes, Scanners), Detection Devices, Reagents And Kits 2) By Software: Image Analysis Software, Data Management Software, Visualization And Interpretation Software 3) By Services: Technical Support And Maintenance, Consultation And Training, Imaging And Analysis Services

What Is The Driver Of The Multiplex Biomarker Imaging Market?

The rising prevalence of chronic diseases is expected to propel the growth of the multiplex biomarker imaging market going forward. Chronic diseases are long-lasting health conditions that persist or recur over time, often with complex causes, multiple risk factors, and long latency periods. The growing prevalence of chronic diseases is attributed to several factors, including the rapid aging of the population, improved case finding and detection, better treatment and management of diseases, and changes in lifestyle and environmental risk factors. Multiplex biomarker imaging is utilized in chronic disease management for comprehensive analysis and characterization of disease progression and treatment response. For instance, in January 2023, according to a report published by the National Institutes of Health (NIH), a US-based biomedical research agency, the number of people aged 50 and older with at least one chronic illness is predicted to rise by 99.5%, from 71.52 million in 2020 to 142.66 million in 2050. Therefore, the rising prevalence of chronic diseases is driving the growth of the multiplex biomarker imaging industry.

Key Players In The Global Multiplex Biomarker Imaging Market

Major companies operating in the multiplex biomarker imaging market are Merck KGaA, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company (BD), Carl Zeiss AG, Illumina Inc, PerkinElmer Inc., Bio-Rad Laboratories Inc, Bruker Corporation, Bio-Techne Corporation, Leica Biosystems Nussloch GmbH, Abcam Plc, Meso Scale Diagnostics LLC, Fluidigm Corporation, NanoString Technologies, Quanterix Corporation, Akoya Biosciences, Enzo Biochem Inc, Cisbio Bioassays, Flagship Biosciences, Aushon BioSystems Ltd, Ionpath Inc., Biosims Technologies

Global Multiplex Biomarker Imaging Market Trends and Insights

Major companies operating in the multiplex biomarker imaging market are focusing on providing innovative slides, such as automated slide loaders, to provide advanced imaging solutions and better serve customers. Automated slide loaders streamline sample handling, reducing hands-on time and enhancing throughput, which is crucial for high-volume multiplex biomarker imaging experiments. For instance, in April 2024, Standard BioTools Inc., a US-based provider of analytical systems and instruments, launched a Hyperion XTi Imaging System with a new high-throughput multiplexed whole slide to add automation and flexibility. It has three modes for rapid analysis, including preview, tissue, and cell modes. Researchers can visualize tissue heterogeneity quickly and conduct deeper analysis. This novel whole slide imaging method using imaging mass cytometry (IMC) offers up to 10 times higher throughput than cyclic immunofluorescent imaging. Additionally, a new automated slide loader facilitates high-throughput imaging, reducing hands-on time and enabling standardization. These innovations aimed to accelerate breakthroughs in spatial proteomics, providing reliable insights into health and disease.

What Are Latest Mergers And Acquisitions In The Multiplex Biomarker Imaging Market?

In March 2024, Calyx, a UK-based provider of medical imaging services, merged with Invicro to create a global leader in medical imaging and software solutions. This combined expertise and broader best-in-class specialist support creates a compelling customer proposition for the greater biopharma industry, ranging from large pharma companies to specialty biotech firms, and this exciting union will also create a truly differentiated industry leader and provide a clear response to growing customer requirements for broader support. Invicro is a US-based next-generation quantitative imaging biomarker company that provides multiplex biomarker imaging services.

Regional Outlook

North America was the largest region in the multiplex biomarker imaging market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Multiplex Biomarker Imaging Market?

The multiplex biomarker imaging market consists of revenues earned by entities by providing services such as imaging and analysis services, pathology services, and clinical and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The multiplex biomarker imaging market also includes sales of imaging instruments, reagents and kits, software, and analysis tools that are used in providing multiplex biomarker imaging services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Multiplex Biomarker Imaging Market Report 2026?

The multiplex biomarker imaging market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the multiplex biomarker imaging industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.